Spero Therapeutics (United States)

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison, Peter Ruane, B. Freilich et al. · Nature Medicine · 2021 · 320 citations

Hepatology, Liver Physiology, Pharmacology +4

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Stephen A. Harrison, Juan P. Frías, Guy Neff et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 198 citations

Medicine, Non-alcoholic Steatohepatitis, Pharmacotherapy +3

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017

Ian A. Critchley, Nicole Cotroneo, Michael J. Pucci et al. · PLoS ONE · 2019 · 155 citations · Full text

Escherichia Coli, Antibiotic Resistance, United States +20

Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741

David F. Corbett, Andrew K. Wise, Tara Langley et al. · Antimicrobial Agents and Chemotherapy · 2017 · 148 citations · Full text

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

Allegra Kaufman, Lubna Abuqayyas, William S. Denney et al. · Cell Reports Medicine · 2020 · 121 citations · Full text